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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide.
Adoption of sedentary life style and westernized diet are shown to be associated with development of NAFLD.
Since previous studies suggested that calcium (Ca) to magnesium (Mg) ratio intake is associated with some chronic
diseases including dyslipidemia and insulin resistance, we designed this study to find any possible association
between this ratio and NAFLD development.
Methods: The NAFLD was diagnosed using Fibroscan according to a CAP cut-off value of 263 dB/m. Dietary intakes
of one hundred and ninety-six patients with incident NAFLD diagnosis, and eight hundred and three controls
without NAFLD were assessed using a valid food frequency questionnaire (FFQ). Dietary nutrients were calculated
using Nutritionist IV software.
Results: Age of the study population (57 % female) was 43.2 ± 14.1 years. In addition, energy-adjusted daily calcium
to magnesium intake ratio was 2.34 ± 0.57 and 2.73 ± 0.69 for control and case groups, respectively. In the
multivariable-adjusted model, after adjustment for potential confounding variables; including, age, gender, BMI,
alcohol consumption, smoking, diabetes, physical activity, energy, dietary fiber, carbohydrate, fat, and protein
intakes, participants in the third (Q3) and fourth (Q4) quartile of Ca/Mg ratio intake had a greater development of
incidental NAFLD compared to the lowest quartile (Q1) [(OR = 2.86; 95 % CI: 1.20–6.81), (P-value = 0.017) and (OR =
5.97; 95 % CI: 2.54–14.01), (P-value < 0.001) for Q3 and Q4 compared to the Q1, respectively]. Moreover, energy-
adjusted Ca to Mg intake ratio was positively correlated with plasma level of ALT (r = 0.18; P = 0.01); contrarily, it had
no correlation with plasma levels of AST.
Conclusions: The current study revealed that higher dietary Ca to Mg intake ratio is associated with a greater
development of NAFLD. Further interventional studies are needed to confirm the causal relationship of the Ca/Mg
ratio intake and development of NAFLD.
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Background
Non-alcoholic fatty liver disease (NAFLD) includes the
entire spectrum of fatty liver disease in patients without
significant alcohol consumption, ranging from fatty liver
to steatohepatitis to cirrhosis [1]. NAFLD is one of the
most common causes of liver cirrhosis and liver cancer
[2–4]. The mortality rate of cirrhosis and cirrhosis-
related diseases such as liver cancer has increased over
the past 35 years worldwide [5]. Obesity, type 2 diabetes,
overmedication, and exposure to the toxic substances
constitute the etiology of NAFLD [6–8]. Patients with
metabolic syndrome are much more likely to develop
NAFLD [9, 10].It has been estimated that NAFLD will
be one of the leading causes of liver disease and its con-
sequent mortality by 2030, along with the obesity epi-
demic [11]. There is also a population so called “lean
NAFLD” [12]. It has been shown that weight reduction
is also beneficial in this population [13]. The first line in
the treatment of NAFLD is dietary interventions and re-
ducing central obesity [14]. Although the pathogenic
role of macronutrients in NAFLD and obesity are clear,
the contribution of micronutrients in the pathogenesis
of NAFLD has garnered less attention than that of obes-
ity [15]. Overall, micronutrients play an important role
in NAFLD pathogenesis [16].
Magnesium (Mg) is an abundant cation in the human
body that plays essential roles in multiple physiological
pathways such as cellular energy metabolism, inflamma-
tion, nucleic acid metabolism, protein synthesis, and
electrolyte balance [17]. Serum Mg concentration is
strictly controlled; however, hypomagnesemia may occur
as a result of increased renal excretion or decreased di-
gestive absorption of magnesium [18]. Hypomagnesemia
and subclinical Mg deficiency are associated with osteo-
porosis, seizure, depression, diabetes mellitus, hyperten-
sion, dyslipidemia, and colorectal cancer [19–21]. On
the other hand, an observational study found that higher
intakes of Mg are associated with a lower development
of NAFLD in young adults [22].
Calcium (Ca) is another major mineral that is mainly
deposited in bone and plays a key role in various biological
processes [23]. Ca and Mg could be regarded as antagonist
to each other in various biochemical pathways [24]. Stud-
ies show that altered serum calcium is associated with dys-
lipidemia and insulin resistance [25]. Previous studies on
human subjects indicate that a high Ca intake may affect
the absorption rate of Mg, which in turn, can be associ-
ated with an increased risk of several diseases [26–29].
Taking all these facts into account, it is plausible to con-
sider the intake ratio of calcium to magnesium as a poten-
tial contributor to NAFLD pathogenesis [28].
Due to the novelty of the idea, we decided to examine
the possible relationship between calcium to magnesium
intake ratio and development of NAFLD in this study.
Materials/subjects and methods
This case–control study was conducted at two clinics in
Tehran province of Iran. The study included 196 cases
with NAFLD and 803 controls. These participants were
selected with the convenience sampling procedure. We
conducted this case-control study on patients with re-
cently diagnosed NAFLD and age-matched controls sub-
jects from the same clinic. The absence of hepatic
steatosis in individuals in the control group was deter-
mined using the ultrasound exam. The presence of
NAFLD in our cases was confirmed by a gastroenterolo-
gist; moreover, the inclusion criteria included having a
Controlled Attenuation Parameter (CAP) score of more
than 263, fibrosis score more than 7, determined by the
Fibroscan device, and the intake of alcohol less than 20
gram/day in women, and less than 30 gram/day in men.
Fibroscan is an ultrasound device calibrated to measure
hepatic steatosis levels producing an index called CAP;
CAP score indicates the level of infiltration of fat in he-
patocytes and has sensitivity and specificity ranged be-
tween 78 and 100 % [30]. All tests were performed by
one operator with Fibroscan (EchoSens, Paris, France)
device. Patients fasted for at least 3 h before the test. Pa-
tients were lying on the bed for at least 3 min before the
test. The probes were calibrated before starting work.
The other secondary causes of hepatic fat accumulation
such as long-term use of a steatogenic medication (e.g.,
mipomersen, lomitapide, amiodarone, methotrexate,
tamoxifen, corticosteroids, valproate and anti-retroviral
medicines), or Hepatitis C (genotype 3) or Wilson dis-
ease or lipodystrophy or starvation or abetalipoproteine-
mia or Reye syndrome or inborn errors of metabolism
were our exclusion criteria [1].
A validated food frequency questionnaire (FFQ) was
used to assess the dietary intake of the participants [31].
Additionally, calorie-density of the two minerals (the
amount of each mineral in an energy intake of 1000
Kcals) and their ratio were calculated for further
analysis.
Baseline characteristics of all participants, including
data on age, employment, marital status, education,
smoking, past medical history, current use of medica-
tions and other factors were obtained by the inter-
viewers. Physical activity level was assessed using
physical activity questionnaire and was later quantified
as metabolic equivalent hours per week (METs h/wk).
Observational studies were reported according to
STROBE guidelines.
Baseline characteristics and dietary intakes between
two study groups were compared using student t-test for
continuous variables and chi-square for categorical var-
iables.We used SPSS (Version 21.0; Chicago, IL, USA)
software to conduct the satatistical analyses.The study
participants were divided into four categories based
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onquartiles of daily energy-adjusted calcium to magne-
sium ratio and the lowest quartile was set as the refer-
ence category in order to evaluate the association
between energy-adjusted daily calcium to magnesium in-
take ratio and NAFLD development. We took advantage
of ANOVA test to compare the inter-quartile relation-
ships. Odds ratios (ORs) and 95 % confidence intervals
(CIs) were calculated using multiple logistic regression
analysis. Analyses were adjusted for all known confound-
ing factors. P-value less than 0.05 considered as
significant.
Results
Baseline participants’ characteristics in case and control
group are shown in Table 1. The participants in case
group had higher levels of BMI, fasting blood sugar
(FBS), triglyceride (TG), low-density lipoprotein–choles-
terol (LDL-c), physical activity (PA), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST),
smoking, diabetes, male, protein, calcium and calcium to
magnesium intake ratio and lower levels of high-density
lipoprotein–cholesterol (HDL-c), carbohydrate and fat
intake (P < 0.05). Baseline characteristics regarding
energy-adjusted daily calcium to magnesium intake ratio
quartiles are presented in Table 2. Mean ± SD age of the
study population (57 % female) was 43.2 ± 14.1 years. In
addition, mean ± SD of energy-adjusted daily calcium to
magnesium intake ratio was 2.34 ± 0.57 and 2.73 ± 0.69
for control and case groups, respectively.
Inter-quartile analyses revealed that participants with
higher daily calcium to magnesium intake ratio had sig-
nificantly higher prevalence of smoking (P < 0.001),
higher levels of BMI (P = 0.006), and higher levels of
LDL-c (P = 0.033) compared to those with lower daily
calcium to magnesium intake ratio. Significant differ-
ences were also detected regarding dietary intakes of en-
ergy (P = 0.024), carbohydrate (P < 0.025), fat (P = 0.042),
and dietary fiber (P = 0.001) when inter-quartile data
were analyzed. Compared by the same criteria, no other
statistically significant differences were found.
Firstly, we evaluated the associations of energy ad-
justed calcium and magnesium intake with the develop-
ment of NAFLD (Tables 3 and 4). Regarding to the
energy adjusted calcium intake, in the final model ad-
justments for potential confounding variables; including,
age, gender, BMI, alcohol consumption, smoking,






Age (years) 42.3 ± 11.9 43.5 ± 14.5 0.214
Male (%) 51.5 41.0 0.007
Body mass index (kg/m2) 35.7 ± 10.6 27.7 ± 4.5 < 0.001
Fasting blood glucose (mg/dl) 108.5 ± 37.6 90.2 ± 29.4 < 0.001
Triglycerides (mg/dl) 176.0 ± 117.9 132.0 ± 81.8 < 0.001
Total cholesterol (mg/dl) 185.7 ± 52.8 177.5 ± 38.9 0.118
High Density Lipoprotein–Cholesterol (mg/dl) 41.9 ± 16.1 47.7 ± 10.5 0.001
Low Density Lipoprotein–Cholesterol(mg/dl) 120.9 ± 41.6 104.0 ± 31.9 < 0.001
Physical activity (MET(hour/week)) 31.0 ± 3.2 34.2 ± 3.1 < 0.001
Alanine aminotransferase (U/L) 55.71 ± 8.27 20.49 ± 7.59 < 0.001
Aspartate aminotransferase (U/L) 33.86 ± 23.69 22.14 ± 7.72 < 0.001
Current alcohol usage (%) 12.8 9.1 0.07
Current smoking (%) 89.7 18.8 < 0.001
Diabetes (%) 16.6 6.8 < 0.001
Energy (Kcal/d) 2757 ± 961.1 2804 ± 840.7 0.499
Protein (% of energy) 15.8 ± 2.9 14.1 ± 2.3 < 0.001
Carbohydrate (% of energy) 58.2 ± 6.3 59.8 ± 13.3 0.014
Fat (% of energy) 29.2 ± 5.3 33.8 ± 5.7 < 0.001
Total dietary fiber (g/d) 46.29 ± 19.07 55.69 ± 46.11 0.08
Magnesium (mg/d) 484 ± 155 509 ± 173 0.09
Calcium (mg/d) 1389 ± 458 1114 ± 390 < 0.001
Calcium to Magnesium ratio 2.79 ± 0.68 2.34 ± 0.57 < 0.001
Quantitative data are presented as mean ± SD and qualitative data reported as percent
*Independent sample t-test and chi-square or Fisher exact test for quantitative and qualitative parameters, respectively
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Table 2 Baseline participants’characteristics across quartiles of energy-adjusted daily calcium to magnesium ratio intake
Quartiles of energy-adjusted daily calcium to magnesium ratio intake
Characteristics Q1 (n = 250) Q2 (n = 249) Q3 (n = 250) Q4 (n = 250) P value*
Age (years) 45.1 ± 13.7 41.9 ± 14.3 43.5 ± 14.1 43.3 ± 14.3 0.16
Male (%) 42.4 45 46.8 38 0.21
Body mass index (kg/m2) 28.7 ± 5.2 27.8 ± 5.3 28.4 ± 5.8 29.1 ± 6.7 0.006
Fasting blood glucose (mg/dl) 94.4 ± 34.6 92.9 ± 34.1 89.8 ± 30 92.3 ± 27.1 0.44
Triglycerides (mg/dl) 139 ± 92.1 140 ± 109.6 133 ± 71.9 131 ± 67.9 0.69
Total cholesterol (mg/dl) 179 ± 36.3 178 ± 44.4 175 ± 33.9 183 ± 37.1 0.33
High Density Lipoprotein–Cholesterol
(mg/dl)
46.7 ± 10.2 46.4 ± 11.2 47.2 ± 10.3 49.1 ± 11.8 0.44
Low Density Lipoprotein–Cholesterol
(mg/dl)
104 ± 30.7 103 ± 35.6 101 ± 29.6 107 ± 29.5 0.033
Physical activity (MET(hour/week)) 32.1 ± 4.4 34.9 ± 3.3 31 ± 3.9 33.8 ± 2.1 0.22
Alanine aminotransferase (U/L) 22.9 ± 23.1 23.7 ± 28.6 24.2 ± 14.1 23.4 ± 19.1 0.08
Aspartate aminotransferase (U/L) 23.1 ± 10.3 23.6 ± 13.6 23.5 ± 9.2 22.1 ± 8.9 0.95
Current alcohol usage (%) 9.6 10.4 9.2 10 0.97
Current smoking (%) 25.6 32.1 28.8 44.2 < 0.001
Diabetes (%) 10.8 7.6 7.6 8.9 0.53
Energy (Kcal/d) 2712 ± 857 2846 ± 815 2876 ± 930 2758 ± 769 0.024
Protein (% of energy) 14.8 ± 1.5 14.4 ± 3.3 15.1 ± 1.7 14.9 ± 6.3 0.16
Carbohydrate (% of energy) 58.6 ± 12.3 56.8 ± 10.9 54.9 ± 8.2 59.1 ± 8.7 0.025
Fat (% of energy) 29.4 ± 1.3 32.5 ± 2.1 30.9 ± 7.6 29.1 ± 4.2 0.042
Total dietary fiber (g/d) 43.6 ± 16 45.4 ± 17.6 50.1 ± 36.8 50.1 ± 21.1 0.001
Magnesium (mg/d) 521 ± 178 508 ± 154 491 ± 167 434 ± 130 < 0.001
Calcium (mg/d) 879 ± 315 1106 ± 340 1249 ± 419 1404 ± 412 < 0.001
Calcium to Magnesium ratio 1.69 ± 0.20 2.17 ± 0.11 2.54 ± 0.12 3.25 ± 0.38 < 0.001
Quantitative data are presented as mean ± SD and qualitative data reported as percent
*one way ANOVA test and chi-square or Fisher exact test for quantitative and qualitative parameters, respectively
Table 3 The development of non- alcoholic fatty liver disease across quartiles of energy-adjusted daily calcium intake
Energy-adjusted daily calcium intake
Q1(n = 249) Q2(n = 250) P-value* Q3(n = 250) P-value* Q4(n = 250) P-value*
Cases/control 18/231 25/225 49/201 104/146
Range of energy-
adjusted Ca
135.8 to 347.3 347.7 to 407.3 407.4 to 473.4 473.9 to 1034.2




























Data are presented as odds ratio (95 %CI)
*Logistic regression
acrude model
bAdjusted for age and gender
cAdditionally adjusted for body mass index, alcohol consumption, smoking, diabetes and physical activity
dAdditionally adjusted for energy, dietary fiber, carbohydrate, fat, and protein intakes
The significance level: P < 0.05
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diabetes, physical activity, energy, dietary fiber, carbohy-
drate, fat, and protein intakes, a positive association was
detected between dietary calcium intake and the devel-
opment of NAFLD in the third (Q3) and fourth (Q4)
quartile compared to the lowest quartile (Q1) [(OR =
3.03; 95 % CI: 1.25–7.36), (P-value = 0.014) and (OR =
5.41; 95 % CI: 3.87–10.87), (P-value < 0.001) for Q3 and
Q4 compared to the Q1, respectively] (Table 3). How-
ever, analyzes showed a negative association between the
energy adjusted dietary magnesium intake and the devel-
opment of NAFLD in fourth (Q4) quartile compared to
the lowest quartile (Q1) [(OR = 0.89; 95 % CI: 1.25–
4.78), (P-value = 0.043)] (Table 4).
The data regarding the association between energy-
adjusted calcium to magnesium intake ratio and the de-
velopment of NAFLD is presented in Table 5. In the
crude model, a positive association was detected be-
tween dietary calcium to magnesium intake ratio and
the development of NAFLD in the third (Q3) and fourth
(Q4) quartile compared to the lowest quartile (Q1)
[(OR = 2.01; 95 % CI:1.21–3.34), (P-value = 0.007) and
(OR = 4.33; 95 % CI:2.68–6.97), (P-value < 0.001) for Q3
and Q4compared to the Q1, respectively].In the
multivariable-adjusted model, after adjustment for po-
tential confounding variables; including, age, gender,
BMI, alcohol consumption, smoking, diabetes, physical
Table 4 The development of non- alcoholic fatty liver disease across quartiles of energy-adjusted daily magnesium intake
Energy-adjusted daily magnesium intake
Q1(n = 250) Q2(n = 249) P-value* Q3(n = 250) P-value* Q4(n = 250) P-value *
Cases/control 70/180 65/185 55/194 36/214
Range of energy-
adjusted Mg
86.31 to 154.40 154.43 to 174.70 174.71 to 196.63 196.65 to 329.96




























Data are presented as odds ratio (95 %CI)
*Logistic regression
acrude model
bAdjusted for age and gender
cAdditionally adjusted for body mass index, alcohol consumption, smoking, diabetes and physical activity
dAdditionally adjusted for energy, dietary fiber, carbohydrate, fat, and protein intakes
The significance level: P < 0.05
Table 5 The development of non- alcoholic fatty liver disease across quartiles of energy-adjusted daily calcium to magnesium ratio
intake
Energy-adjusted daily calcium to magnesium ratio intake
Q1(n = 250) Q2(n = 249) P-value* Q3(n = 250) P-value* Q4(n = 250) P-value*
Cases/control 27/223 34/215 49/201 86/164
Range of Ca to Mg ratio 0.95 to 1.97 1.97 to 2.36 2.36 to 2.81 2.82 to 5.02




























Data are presented as odds ratio (95 %CI)
*Logistic regression
acrude model
bAdjusted for age and gender
cAdditionally adjusted for body mass index, alcohol consumption, smoking, diabetes and physical activity
dAdditionally adjusted for energy, dietary fiber, carbohydrate, fat, and protein intakes
The significance level: P < 0.05
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activity, energy, dietary fiber, carbohydrate, fat, and pro-
tein intakes, participants in the third (Q3) and fourth
(Q4) quartile had a greater development of incidental
NAFLD compared to the lowest quartile (Q1)[(OR =
2.86; 95 % CI: 1.20–6.81), (P-value = 0.017) and (OR =
5.97; 95 % CI: 2.54–14.01), (P-value < 0.001) for Q3 and
Q4 compared to the Q1, respectively].
To investigate the relationship between the energy-
adjusted calcium to magnesium intake ratio and plasma
levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), the Pearson correlation test was
conducted. Energy-adjusted calcium to magnesium in-
take ratio was positively correlated with plasma level of
ALT (r = 0.18; P = 0.01); contrarily, it had no correlation
with plasma levels of AST.
Discussion
In this case control study, we observed that subjects with
higher energy-adjusted dietary calcium to magnesium
intake ratio had a greater development for incidental
NAFLD, independent of confounding factors including
age, gender, BMI, alcohol consumption, smoking, dia-
betes, physical activity, energy, dietary fiber, carbohy-
drate, fat, and protein intakes.
Recent studies have shown that the impact of nutri-
tional factors on the incidence of NAFLD is more pro-
nounced [32–35]. To the best of our knowledge, there is
no study that has examined the relationship between the
calcium to magnesium intake ratio and the development
of NAFLD; however, calcium and magnesium were sep-
arately investigated as potential mediators in the patho-
genesis of the disease. Based on consistent evidence,
intake of magnesium was inversely associated to the fac-
tors related to the risk of insulin resistance [36], and
metabolic syndrome, specifically factors such as high
fasting glucose level, high waist circumference, and low
high-density lipoprotein cholesterol [37, 38]. Lu et al.
found that higher intakes of Mg during adulthood is re-
lated to a lower risk of NAFLD in middle age [22].
Moreover, in another study, subjects with NAFLD or al-
coholic fatty liver were at higher risk of developing
magnesium deficiency [39]. However, another study con-
ducted in Canada was not able to find any links between
magnesium intake and risk of NAFLD; considering the
structural weaknesses in this study, the results might
lack enough credibility to be deductible [40].
As mentioned beforehand in the present article,
calcium has some biochemical interactions with magne-
sium. These interactions might have clinical manifesta-
tions concerning the pathogenesis of several metabolic
disorders. Wenshuai Li et al. who investigated the data
related to the Third National Health and Nutrition
Examination Survey (NHANES III) follow-up US adults’
cohort [41], found out that the intake of magnesium was
associated to an approximately 30 % reduced risk of
NAFLD and prediabetes, only in subjects who consumed
less than 1200 mg/day calcium. Their findings suggested
that beneficial effect of magnesium might be attenuated
when calcium intake is higher than the amount recom-
mended by Dietary Reference Intakes (DRIs). One of the
important mechanisms might be the suppressive effects
of high calcium intake on the gastrointestinal absorption
and renal reabsorption of magnesium which may alter
the excretion of the ion in the feces and urine [24, 42].
As evident by the results of the present study, the Ca:
Mg intake ratio might be a useful indicator to observe
the combined impact of these two major minerals may
exert upon different physiologic, as well as pathologic
pathways. USDA food surveys from 1977 to 2007-8 show
a rising food Ca:Mg ratio from 2.3 to 2.9 to 2.9–3.5 for
all USA adults; these figures might be worthy of concern
as they coincide with the rise of several metabolic dis-
eases such as diabetes and colorectal cancer [43]. Fur-
thermore, there is growing evidence indicating that
modifications in serum Ca:Mg ratio is associated with
some disorders including diabetes and metabolic syn-
drome [44], breast cancer [45, 46], cardiovascular dis-
eases [47], and higher mortality [29]. Even though the
optimal calcium to magnesium intake ratio is yet to be
specified, some studies have suggested a 2:1 ratio as the
optimum ratio [47]. Consistent with previous studies,
our study indicated that participants in the third and
fourth quartiles of Ca:Mg intake ratio (ranging from 2.36
to 5.02) had a significantly higher risk of NAFLD as
compared to the first quartile.
The regulation of calcium and magnesium homeosta-
sis in the body is interdependent. Calcium-sensitive re-
ceptor, also known as CaSR, is responsible to monitor
plasma levels of both cations [48].Whenever the plasma
level of each of the cations drops, CaSR up regulates the
related mechanisms leading to an increase in its blood
level, regardless of the other cation concentration in the
blood [49, 50]. Furthermore, a drop in serum Mg could
also decrease intracellular levels of Mg reducing the cel-
lular Mg–ATP deposits. This may lead to an increase in
Ca influx, which, in turn, may upgrade the Ca–ATP level
of the cell. Increased intracellular calcium levels have
been proposed an underlying mechanism for the patho-
genesis of several metabolic and inflammatory disorders
such as obesity, metabolic syndrome, diabetes, and
NAFLD [45, 51–53].
This is the first observational study that evaluated the
relationship between Ca:Mg intake ratio and the devel-
opment of NAFLD. We were able to conduct the present
research on a statistically acceptable sample size of sub-
jects with corresponding socio-economic status. More-
over, the use of top-notch devices to determine the
presence or the lack of the disease improved the
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accuracy and the precision of our inclusion/exclusion
criteria. The present study also has some limitations.
Case-control studies may prove an association but they
do not demonstrate causation. Proving the causal rela-
tionship requires future intervention studies. Although
we used a validated FFQ for measurement of dietary in-
takes, recall bias and measurement error are inevitable
errors. Furthermore, although we tried to control the ef-
fect of major confounding factors, the effects of un-
known factors and residual confounding cannot be ruled
out. We also suggest that liver stiffness measurement
(LSM) by Fibroscan be used in future studies for accur-
ate prediction of liver fibrosis severity. Calculation of
Fibrosis-4 (FIB-4) or NAFLD fibrosis score (NFS) which
are indicators of advanced fibrosis in NAFLD patients
used in exclusion of advanced fibrosis owing to its high
negative predictive value is also recommended [54–56].
Conclusions
The current study revealed that higher dietary calcium
to magnesium intake ratio is associated with a greater
development of NAFLD. Further interventional studies
are needed to confirm the causal relationship between
the dietary calcium to magnesium intake ratio and inci-
dental NAFLD.
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